| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786226 | Clinical Oncology | 2018 | 7 Pages |
Abstract
Pemetrexed-platinum-based NACT seems to be an effective option and many borderline cases, where upfront definitive therapy is not feasible, may become amenable to the same after incorporation of NACT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
V. Noronha, S. Zanwar, A. Joshi, V.M. Patil, A. Mahajan, A. Janu, J.P. Agarwal, P. Bhargava, A. Kapoor, K. Prabhash,